279 related articles for article (PubMed ID: 38528616)
21. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
22. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study.
Do LAH; Vodicka E; Nguyen A; Le TNK; Nguyen TTH; Thai QT; Pham VQ; Pham TU; Nguyen TN; Mulholland K; Cao MT; Le NTN; Tran AT; Pecenka C
BMC Infect Dis; 2023 Feb; 23(1):73. PubMed ID: 36747128
[TBL] [Abstract][Full Text] [Related]
23. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.
Hall CB; Weinberg GA; Blumkin AK; Edwards KM; Staat MA; Schultz AF; Poehling KA; Szilagyi PG; Griffin MR; Williams JV; Zhu Y; Grijalva CG; Prill MM; Iwane MK
Pediatrics; 2013 Aug; 132(2):e341-8. PubMed ID: 23878043
[TBL] [Abstract][Full Text] [Related]
24. Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy.
Ciarlitto C; Vittucci AC; Antilici L; Concato C; Di Camillo C; Zangari P; Villani A
Ital J Pediatr; 2019 Aug; 45(1):115. PubMed ID: 31462274
[TBL] [Abstract][Full Text] [Related]
25. Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins.
Dotan M; Ashkenazi-Hoffnung L; Samra Z; Livni G; Yarden-Bilavsky H; Amir J; Bilavsky E
Isr Med Assoc J; 2013 Nov; 15(11):701-4. PubMed ID: 24511652
[TBL] [Abstract][Full Text] [Related]
26. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.
Maksić H; Heljić S; Skokić F; Šumanović-Glamuzina D; Milošević V; Zlatanović A; Gerard N
Bosn J Basic Med Sci; 2018 Aug; 18(3):279-288. PubMed ID: 29750895
[TBL] [Abstract][Full Text] [Related]
27. Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
Simões EAF; Chirikov V; Botteman M; Kwon Y; Kuznik A
J Infect Dis; 2020 Mar; 221(8):1256-1270. PubMed ID: 31165865
[TBL] [Abstract][Full Text] [Related]
28. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
29. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
30. RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies.
Ali A; Yousafzai MT; Waris R; Jafri F; Aziz F; Abbasi IN; Zaidi A
J Med Virol; 2017 Jul; 89(7):1151-1157. PubMed ID: 28092107
[TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus: can we still believe that after pandemic bronchiolitis is not a critical issue for public health?
Vittucci AC; Antilici L; Russo C; Musolino AMC; Cristaldi S; Cutrera R; Persia S; Di Maio CV; Raponi M; Perno CF; Villani A
Eur J Pediatr; 2023 Dec; 182(12):5303-5313. PubMed ID: 37728752
[TBL] [Abstract][Full Text] [Related]
32. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
Ares-Gómez S; Mallah N; Pardo-Seco J; Malvar-Pintos A; Pérez-Martínez O; Otero-Barrós MT; Súarez-Gaiche N; Santiago-Pérez MI; González-Pérez JM; López-Pérez LR; Rosón B; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
Pediatr Allergy Immunol; 2024 May; 35(5):e14131. PubMed ID: 38700124
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy.
Azzari C; Baraldi E; Bonanni P; Bozzola E; Coscia A; Lanari M; Manzoni P; Mazzone T; Sandri F; Checcucci Lisi G; Parisi S; Piacentini G; Mosca F
Ital J Pediatr; 2021 Oct; 47(1):198. PubMed ID: 34600591
[TBL] [Abstract][Full Text] [Related]
35. Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii.
Yorita KL; Holman RC; Steiner CA; Effler PV; Miyamura J; Forbes S; Anderson LJ; Balaraman V
Pediatr Infect Dis J; 2007 Dec; 26(12):1081-8. PubMed ID: 18043442
[TBL] [Abstract][Full Text] [Related]
36. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
[TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.
Benítez-Guerra D; Piña-Flores C; Zamora-López M; Escalante-Padrón F; Lima-Rogel V; González-Ortiz AM; Guevara-Tovar M; Bernal-Silva S; Benito-Cruz B; Castillo-Martínez F; Martínez-Rodríguez LE; Ramírez-Ojeda V; Tello-Martínez N; Lomelí-Valdez R; Salto-Quintana J; Cadena-Mota S; Noyola DE
Influenza Other Respir Viruses; 2020 Mar; 14(2):182-188. PubMed ID: 31917902
[TBL] [Abstract][Full Text] [Related]
38. Respiratory Syncytial Virus Infection Among Hospitalized Infants in Four Middle-Income Countries.
Biggs HM; Simões EAF; Abu Khader I; Thompson MG; Gordon A; Hunt DR; DeGroote NP; Porter RM; Bino S; Marar BI; Gresh L; de Jesus-Cornejo J; Langley G; Thornburg NJ; Peret TCT; Whitaker B; Zhang Y; Wang L; Patel MC; McMorrow M; Campbell W; Hasibra I; Duka E; Al-Gazo M; Kubale J; Sanchez F; Lucero MG; Tallo VL; Azziz-Baumgartner E; Simaku A; Gerber SI;
J Pediatric Infect Dis Soc; 2023 Jul; 12(7):394-405. PubMed ID: 37313727
[TBL] [Abstract][Full Text] [Related]
39. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
[TBL] [Abstract][Full Text] [Related]
40. Incidence of respiratory syncytial virus bronchiolitis in hospitalized infants born at 33-36 weeks of gestational age compared with those born at term: a retrospective cohort study.
Greenberg D; Dagan R; Shany E; Ben-Shimol S; Givon-Lavi N
Clin Microbiol Infect; 2020 Feb; 26(2):256.e1-256.e5. PubMed ID: 31181285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
